2021-11-11On November 11th 2021, Genhouse Bio, a biotech company focusing on development of next-generation small molecule anti-cancer therapeutics, announced today that the Center for Drug Evaluation (CDE) has recently approved IND application for Class I new drug GH21. The U.S. IND application for GH21, submitted by Genhouse’s strategic partner HUYABIO, has also been approved by FDA in October. GH21 has now received IND approval in both China and the U.S.
The leading PI of phase I clinical study of GH21 in China, Dr. Lin Shen, Vice President of Peking University Cancer Hospital said, “we anticipate to see positive safety and efficacy result of GH21 in the clinical study. We will continue to explore the value of targeted therapies and combination therapies in cancer treatment to benefit more patients.”
“SHP2 is not only downstream of multiple RTK signaling pathways, but also participate in tumor immune escape, ” said Dr. Kuifeng Wang, founder and CEO of Genhouse, “we believe SHP2 has very high clinical potential. In preclinical study, we tested GH21 in multiple CDX and PDX models and accumulated a wealth of knowledge about biomarker, which will provide much help in clinical development. The IND approval of GH21 in China is another critical milestone in its development.”
About SHP2
SHP2, also known as Tyrosine-protein phosphatase non-receptor type 11 (PTPN11), is the first oncogenic tyrosine-protein phosphatase discovered in history. Recently, SHP2 has drawn broad attention. On one hand, it is at the downstream of most RTK pathways, transducing cell proliferative and survival signals for RAS-MAPK/PI3K-mTOR pathway. On the other hand, SHP2 is also at the downstream of multiple immune checkpoints, such as PD-1 and BTLA, transducing immune escape signal in cancer cells, which gives SHP2 broad combo potential with immune checkpoint inhibitors. Therefore, SHP2 inhibitors are believed to have dual effects in both the RTK pathways and immune oncology.
About GH21
GH21 is a SHP2 allosteric inhibitor developed independently by Genhouse with global IP rights. GH21 has very high selectivity and is effective against multiple SHP2 point mutants. Both in vitro and in vivo studies have shown that GH21 does not affect any other tyrosine-protein phosphatases besides SHP2, thus has very low off-target risk. Moreover, GH21 has very good PK and safety profile, and a broad therapeutic window. Therefore, GH21 is a very promising small molecule drug candidate.
About Genhouse
Genhouse Bio is an innovative biotech company focusing on the development of global next-generation small molecule anti-cancer therapeutics, which has a clear focus on overcoming those “undruggable” target and original innovation. Genhouse is dedicated to establishing a specialized new drug development system, with a SAR research platform based on structural biology, a Drug Screening platform based on target research and a Druggability Evaluation platform including efficacy, metabolic and safety profile evaluation.
By virtue of these platforms, Genhouse has built a highly innovative anti-cancer pipeline and successfully out-licensed the ex-China right of its SHP2 inhibitor GH21 to HuYa Bioscience International, a global biotech company. Genhouse will continue to advance more innovative programs into global development.
Genhouse Bio (Suzhou) Ltd. (“Genhouse” or “We”) respects the privacy of visitors (“Users”) to our website www.genhousebio.com (“Site”), so we have developed this website privacy statement (“Privacy Statement”). This Privacy Statement indicates what information we collect about you and how that information is used. We may update the content of the Privacy Statement and suggest reading it regularly when you visit our Site.
Personal Information Collected by Genhouse
When you visit the Site, usually we will not collect any personal information from you. We might track your DNS and analyze the data to obtain understanding on visit trends. However, your identity will always remain anonymous, unless you specifically and knowingly provide it to us. When you provide such information, we will collect your personal information, such as when you contact us through the phone number or email address posted on the Site. But no matter when and how we collect your personal information, we will always provide link to this Privacy Statement. By willingly providing your personal information to us, you make the consent that we could use the information collected according to this Privacy Statement and admit that the information will be transferred from your locale to our office or server.
Information Disclosures and Sharing
Except as provided below, we will not share or sell your Personal Information with third parties unless otherwise stated by this Privacy Statement.
We might share your information according to this Privacy Statement, with Related Party who have consented to follow this Privacy Statement. Your personal information might also be transferred to other Related Party who represents us for purpose stated when we collect those information or other purposes permitted by law, such as Site evaluation, data management or technical support.
We might sell or buy business or assets during our operation. If Genhouse is acquired, merged, reorganized or dissolved or other alike situations happened, personal information might be part of the assets transferred. We may share personal information to respond to duly authorized subpoenas or other lawful information requests of governmental authorities, including to meet national security or law enforcement requirements, to provide Internet security, or where required by law.
Cookies
We might put a digital tag (more precisely “cookies”) on your hard disk driver for the server to recognize your computer and track usage information. Cookies will not reveal your personal information and you could always stay anonymous to us. The information we collected from Cookies will only be used for internal purpose and improve the service we provided to you through the Site. Users of our Site always have the option of disabling cookies via their browser preferences. If under any circumstances we collected your personal information, we will always inform you with your planned usage, contact and any Third Party that might get this information. All your personal information will maintain secrecy.
Links to Other Websites
If you apply to a job through our Site, you might be directed to other websites operated by Third Party. This Privacy Statement does not extend to any of these websites. Genhouse will not be responsible for any personal information collected by these websites operated by Third Party. Therefore, for any cases that a Third Party collect or use your personal information, Genhouse will not be legally responsible. We advise you to contact those websites directly and get their policies on personal information collection, safety, sharing and disclosure.
Contact Information
If you have any questions about our Privacy Statement, please do not hesitate to contact us at [infor@genhousebio.com].
Effective and Last Updated: April 15th 2021
